ABCL vs SNY
AbCellera Biologics Inc. vs Sanofi — AI-powered side-by-side comparison
ABCL
AbCellera Biologics Inc.
64
Buy
VS
| Metric | ABCL | SNY |
|---|
| AI Score |
64
|
66
|
| Price |
$10.35
|
$43.73
|
| P/E Ratio |
-18.07×
|
22.99×
|
| ROE |
-15.1%
|
10.9%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
75.0%
|
72.8%
|
| Debt / Equity |
0.15×
|
0.34×
|
| Dividend Yield |
0.0%
|
5.5%
|
| RSI (14) |
90.0
|
53.1
|
| Beta |
1.191
|
0.278
|
| Expected Upside |
—
|
+3.9%
|
AI Committee View
Current Innellis committee reasoning for ABCL versus SNY.
SNY leads by 2 points.
SNY scores 66/100 (Buy) versus ABCL at 64/100 (Buy).
ABCL Committee View
67% agreement
6 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- Price-to-book of 1.1x is a discount to asset value — Value
- Revenue growing 101.3% YoY -- genuine top-line momentum — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
Bear Case
- ROE of only -17.5% -- cheap may mean cheap for a reason — Value
- RSI at 90 is in overbought territory — Technical
- Price trading above the upper Bollinger Band -- stretched — Technical
SNY Committee View
67% agreement
6 analysts
The primary driver is low leverage (debt-to-equity 0.28) -- balance sheet can absorb a shock. The main limiting factor is price structure making lower highs and lower lows. The committee is constructive but not yet at full conviction.
Bull Case
- P/E of 9.6 is inexpensive for the broad market — Value
- Price-to-book of 1.4x is a discount to asset value — Value
- Dividend yield of 5.5% pays you to wait — Value
Bear Case
- Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
- Price structure making lower highs and lower lows — Technical
- MACD histogram negative -- bearish momentum — Technical